Transcatheter aortic valve implantation (TAVi)
Medtronic key studies
Stay up to date on the latest clinical evidence from Medtronic. Key summaries demonstrate the efficacy of the CoreValve™/Evolut™ TAVI platform.
Download the Medtronic clinical trial overview brochure.
Evolut™ Low Risk Trial
Evolut™ TAVI shows durable clinical outcomes in low-risk patients at five years.1
5-year all-cause mortality or disabling stroke in Evolut Low Risk Trial
Sample size
N = 730 TAVI, N = 686 SAVR
Devices
Evolut™ R 73%/Evolut™ PRO 23.4%/CoreValve™ 3.6%
Real-world results
Review recent data that reinforces the excellent outcomes seen in our Medtronic clinical trials.
Procedure and performance
Discover our procedural guidance and outcomes you can expect from the Evolut platform.
1. Reardon M. 5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis. Presented at ACC; March 2025.
2. Herrmann HC. SMART 2-year data update. Presented at CRT 2025; March 9, 2025, Washington D.C.
3. Yakubov S, et al. Five-year incidence of bioprosthetic valve dysfunction in patients randomized to surgery or TAVR: insights from the CoreValve US Pivotal and SURTAVI Trials. Presented at CRT; 2023.
4. Grubb K. Impact of a standardized TAVI technique and care pathway in the Optimize PRO study. Presented at EuroPCR 2022; 2022; Paris, France.
5. Van Mieghem NM, Deeb GM, Søndergaard L, et al. Self-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk patients: 5-year outcomes of the SURTAVI Randomized Clinical Trial. JAMA Cardiol. 2022;7(10):1000–1008. doi: 10.1001/jamacardio.2022.2695.
6. Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42(19):1825–1857. doi: 10.1016/j.jacc.2021.02.038.
7. Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(45):3382–3390. doi: 10.1093/eurheartj/ehx303.
8. Adapted from VARC-3 Writing Committee, et al. and Capodanno D, et al.
9. Strange G, Stewart S, Celermajer D, et al. Poor Long-Term Survival in Patients With Moderate Aortic Stenosis. J Am Coll Cardiol. October 15, 2019;74(15);1851-1863
TM* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
DISCLAIMER
The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals.
See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events.
For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic’s website manuals.medtronic.com.
Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative.
© 2024 Medtronic. All rights reserved, Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic.
™*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.